ClinicalTrials.gg
RecruitingNCT07827573kalitERAUpdated Nov 12, 2026

A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

A Phase 3 interventional study of Giredestrant in Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer and HER2-Negative Breast Cancer, sponsored by Hoffmann-La Roche. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Now RecruitingFirst sites in Canada and United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Planned enrollment
2nd of 16
1,500 · median 302
Started
2026
with 1 other
Phase 3
7 of 16
2 open now
Primary completion
2028-11
later than 10 of 11 live
Registered
16th of 16
by date
Lead sponsor
8 of 16
Hoffmann-La Roche

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 3, reaches primary completion later than 10 of the 11 other live ones, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate treatment adherence, tolerability, and patient-reported outcomes of participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC) who are treated with giredestrant.

The study will have two cohorts. Cohort A will comprise a broad upfront patient population with low-, medium-, or high-risk eBC. Cohort B will comprise patients with medium- or high-risk eBC who have completed adjuvant treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) (abemaciclib or ribociclib) and endocrine therapy and who are now switching to giredestrant monotherapy.

03

Conditions studied

  • Early Breast Cancer
  • Estrogen Receptor-Positive Breast Cancer
  • HER2-Negative Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of ER-positive, -negative, Stage I-III, breast cancer
  • Definitive surgery of primary breast tumor(s) and axillary lymph nodes (axillary lymph node dissection and/or sentinel lymph node )
  • Participants must have completed any prior chemotherapy before enrollment, if given
  • (ECOG) Performance Status 0, 1, or 2
  • Adequate organ function
  • Men and pre- or perimenopausal women must receive a concurrent approved luteinizing hormone-releasing hormone agonist

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within the timeframe in which is required
  • Diagnosis of inoperable locally advanced or Stage IV breast cancer
  • History of any prior (ipsilateral and/or contralateral) invasive breast cancer or ductal carcinoma in situ (DCIS)
  • Planned surgery during the study
  • Prior treatment with giredestrant, selective estrogen receptor degraders (SERDs), or endocrine agents
  • Active cardiac disease or history of cardiac dysfunction
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Cohort A: Upfront Adjuvant Endocrine Therapy Population

    Participants will receive giredestrant.

    Drug: Giredestrant

  • Experimental
    Cohort B: Switch Adjuvant Endocrine Therapy Population

    Participants will receive giredestrant.

    Drug: Giredestrant

Interventions

  • Participants will receive giredestrant 30 mg orally once a day for up to 5 years.

    Also known as: RO7197597, GDC-9545, RG6171

06

What researchers measure

Primary outcomes

  1. Incidence of Participants who Have Discontinued Giredestrant for any Reason

    Time frame: Month 12

Secondary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    Time frame: Up to approximately 5 years

  2. Treatment Adherence, as Measured by Dose Intensity

    Time frame: Up to approximately 5 years

  3. Treatment Adherence, as Measured by Treatment Duration

    Time frame: Up to approximately 5 years

  4. Cohort A: Mean Absolute Score for Joint Pain as Assessed by Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES)

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  5. Cohort A: Mean Change From Baseline in Joint Pain Score as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  6. Cohort A: Mean Absolute Score for Hot Flashes as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  7. Cohort A: Mean Change From Baseline in Hot Flashes Score as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  8. Cohort A: Mean Absolute Score for Vaginal Dryness as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  9. Cohort A: Mean Change From Baseline in Vaginal Dryness Score as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  10. Cohort A: Mean Absolute Score for Sexual Dysfunction as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  11. Cohort A: Mean Change From Baseline in Sexual Dysfunction Score as Assessed by FACT-ES

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  12. Cohort A: Mean Absolute Score for the Overall Endocrine Symptom Burden as Assessed by FACT-ES Endocrine Symptom Subscale Score

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  13. Cohort A: Mean Change From Baseline in the Overall Endocrine Symptom Burden Score as Assessed by FACT-ES Endocrine Symptom Subscale Score

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  14. Cohort A: Mean Absolute Score for Pain as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Pain Severity Composite Score

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  15. Cohort A: Mean Change From Baseline in Pain as Assessed by the BPI-SF Pain Severity Composite Score

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  16. Cohort A: Mean Absolute Score for Pain Interference as Assessed by the BPI-SF Pain Interference Composite Score

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  17. Cohort A: Mean Change From Baseline in Pain Interference as Assessed by the BPI-SF Pain Interference Composite Score

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  18. Cohort A: Percentage of Participants Reporting Each Response Option for the Treatment Side-Effect Bother Single-Item GP5 (General Physical Well-Being Item 5) as Assessed by the Functional Assessment of Cancer Therapy-General (FACT-G)

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  19. Cohort A: Change From Baseline in the Treatment Side-Effect Bother Single-Item GP5 as Assessed by FACT-G

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  20. Cohort B: Percentage of Participants Achieving Improvement in Joint Pain Score as Assessed by FACT-ES

    Time frame: Month 6 and Month 12

  21. Cohort B: Percentage of Participants Achieving Improvement in Hot Flashes Score as Assessed by FACT-ES

    Time frame: Month 6 and Month 12

  22. Cohort B: Percentage of Participants Achieving Improvement in Vaginal Dryness Score as Assessed by FACT-ES

    Time frame: Month 6 and Month 12

  23. Cohort B: Percentage of Participants Achieving Improvement in Sexual Dysfunction Score as Assessed by FACT-ES

    Time frame: Month 6 and Month 12

  24. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in Endocrine Therapy-Specific Symptom Burden as Assessed by the FACT-ES Endocrine Symptom Subscale Score

    Time frame: Month 6 and Month 12

  25. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in Pain-Related Burden as Assessed by the BPI-SF Pain Severity Composite Score

    Time frame: Month 6 and Month 12

  26. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in Pain-Related Burden as Assessed by the BPI-SF Pain Interference Composite Score

    Time frame: Month 6 and Month 12

  27. Cohort B: Percentage of Participants Achieving Improvement in Global Treatment Bother as Assessed by the Single-Item GP5 From the FACT-G

    Time frame: Month 6 and Month 12

  28. Cohort A: Mean Absolute Score for Physical Function as Assessed by the European Organization for Research and Treatment of Cancer Item Library 492 (EORTC IL 492)

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  29. Cohort A: Mean Change From Baseline in Physical Function Score as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  30. Cohort A: Mean Absolute Score for Role Function as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  31. Cohort A: Mean Change From Baseline in Role Function Score as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  32. Cohort A: Mean Absolute Score for Cognitive Function as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  33. Cohort A: Mean Change From Baseline in Cognitive Function Score as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  34. Cohort A: Mean Absolute Score for Health-Related Quality of Life (HRQoL) as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  35. Cohort A: Mean Change From Baseline in HRQoL Score as Assessed by EORTC IL 492

    Time frame: At prespecified timepoints from Baseline until approximately 5 years

  36. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in Physical Function as Assessed by EORTC IL 492

    Time frame: Month 6 and Month 12

  37. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in Role Function as Assessed by EORTC IL 492

    Time frame: Month 6 and Month 12

  38. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in Cognitive Function as Assessed by EORTC IL 492 Subscale Score

    Time frame: Month 6 and Month 12

  39. Cohort B: Percentage of Participants Categorized as Improved, Stable, or Worsened in HRQoL as Assessed by EORTC IL 492 Subscale Score

    Time frame: Month 6 and Month 12

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 18, 2026
StartEst.
Nov 30, 2026was Oct 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
4 sites added — first sites in Canada and United States
Show 4 added (2 Canada, 2 United States)
  • CHU de Québec - Hôpital du Saint-Sacrement · Québec, Canada
  • Hematology Oncology Salem · Salem, United States
  • Virginia Cancer Institute · Richmond, United States
  • Jewish General Hospital · Montreal, Canada
across 2 updates, Nov 3, 2026 – Nov 12, 2026
Start date
Oct 30, 2026→Nov 30, 2026
moved 2 times, Nov 3, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    3 sites added — first site in United States
    Show 3 added (2 United States, 1 Canada)
    • Hematology Oncology Salem · Salem, United States
    • Virginia Cancer Institute · Richmond, United States
    • Jewish General Hospital · Montreal, Canada
    Start date Dec 11, 2026→Nov 30, 2026
    + 1 other change: verification date
  2. Nov 3, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Canada
    Show site
    • CHU de Québec - Hôpital du Saint-Sacrement · Québec, Canada
    Start date Oct 30, 2026→Dec 11, 2026
  3. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07827573
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Reference Study ID Number: BO46775 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion